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Abstract
Medullary thyroid cancer (MTC) is associated with activation of mammalian target of rapamycin 
(mTOR) signaling pathways. Recent studies showed that the antidiabetic agent metformin 
decreases proliferation of cancer cells through 5′-AMP-activated protein kinase (AMPK)-
dependent inhibition of mTOR. In the current study, we assessed the effect of metformin on MTC 
cells. For this purpose, we determined growth, viability, migration, and resistance to anoikis assays 
using two MTC-derived cell lines (TT and MZ-CRC-1). Expressions of molecular targets of 
metformin were examined in MTC cell lines and in 14 human MTC tissue samples. We found that 
metformin inhibited growth and decreased expression of cyclin D1 in MTC cells. Treatment with 
metformin was associated with inhibition of mTOR/p70S6K/pS6 signaling and down-regulation of 
pERK in both TT and MZ-CRC-1 cells. Metformin had no significant effects on pAKT in the cell 
lines examined. Metformin-inducible AMPK activation was noted only in TT cells. Treatment 
with AMPK inhibitor (compound C) or AMPK silencing did not prevent growth inhibitory effects 
of metformin in TT cells. Metformin had no effect on MTC cell migration but reduced the ability 
of cells to form multicellular spheroids in nonadherent conditions. Immunostaining of human 
MTC showed over-expression of cyclin D1 in all tumors compared with corresponding normal 
tissue. Activation of mTOR/p70S6K was detected in 8/14 (57.1%) examined tumors. Together, 
these findings indicate that growth inhibitory effects in MTC cells are associated with 
downregulation of both mTOR/6SK and pERK signaling pathways. Expression of metformin’s 
molecular targets in human MTC cells suggests its potential utility for the treatment of MTC in 
patients.
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Introduction
Medullary thyroid cancer (MTC) derives from parafollicular C-cells of the thyroid and 
comprises ∼4% of thyroid cancers in United States (Hundahl et al. 1998). MTC occurs in 
sporadic and hereditary forms. The heritable variants include three different clinical 
phenotypes: multiple endocrine neoplasia type 2A (MEN2A), MEN2B, and familial MTC-
only syndrome (Pelizzo et al. 2007). Prognosis in patients with MTC mainly depends on the 
stage of tumor progression at the time of diagnosis, with a mean 10-year survival rate of 
100, 93, 71, and 21% for stages I, II, III, and IV respectively (Modigliani et al. 1998).
Dominant activating mutations in the RET protooncogene have been identified as the 
underlying cause of the development of MTC (de Groot et al. 2006). The activation of 
antiapoptotic PI3K/AKT pathway and mitogenic MEK/ERK cascade are crucial events in 
cell transformation triggered by oncogenic RET (Segouffin-Cariou & Billaud 2000, Drosten 
et al. 2004). Recent studies demonstrated that the presence of the RET mutation is also 
associated with activation of the mammalian target of rapamycin (mTOR) signaling in MTC 
cells (Grozinsky-Glasberg et al. 2010, Faggiano et al. 2011).
The mTOR protein complex integrates signals from growth factors with protein translation. 
mTOR regulates cell growth through p70-S6 kinase (p70S6K), which leads to 
phosphorylation of ribosomal protein S6 (Wullschleger et al. 2006, Guertin & Sabatini 
2007). The pathway from growth factor receptor stimulation to mTOR activation proceeds 
through PI3K/AKT and MAPK/ERK signaling pathways. AKT phosphorylates and inhibits 
tuberin sclerosis protein complexes (TSC1 and 2) leading to mTOR activation through 
interactions with the mTOR protein complexes mTORC1 and mTORC2 (Astrinidis & 
Henske 2005). In addition to being directly phosphorylated by AKT, TSC2 can be 
phosphorylated and inactivated by ERK as well as its downstream kinase RSK (Shaw & 
Cantley 2006).
Inhibition of signaling pathways activated by oncogenic RET emerged as an alternative 
strategy for the treatment of patients with MTCs (Lanzi et al. 2009). The kinase inhibitor 
that blocks activity of RET kinase (Vandetanib) is being used in clinical practice for the 
treatment of progressive MTC. Multikinase inhibitors targeting VEGFR (Sorafenib), as well 
as mTOR inhibitor (Everolimus), showed antitumor effects in preclinical studies and are in 
clinical trials (Lanzi et al. 2009, Lam et al. 2010, Faggiano et al. 2011). However, only 
partial responses and transient disease stabilization were reported from the clinical trials, and 
most of the MTC patients eventually developed progressive disease (Cabanillas et al. 2010). 
Therefore, the understanding of mechanisms controlling MTC progression vs metastatic 
phenotypes is important for development of new therapeutic approaches.
There is limited information on how cell signaling activation may control invasion of MTC 
cells, and there are no studies that address molecular mechanisms underlying survival of 
MTC cells in blood and lymphatic vessels. We previously demonstrated that invasive thyroid 
cancer cells are characterized by a gene expression signature that is consistent with epithelial 
to mesenchymal transition (Vasko et al. 2007). Studies on various cancer cell lines showed 
that activation of MEK–ERK and PI3/AKT/mTOR signaling pathways contributes to cancer 
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cell resistance to anoikis (apoptosis induced by detachment from extracellular matrix; 
Zugasti et al. 2001, Goldstein et al. 2009, Jensen et al. 2011). It has also been reported that 
concurrent inhibition of MEK–ERK and mTOR/p70S6K pathways selectively targets 
anoikis-resistant cancer cells with acceptable effects on normal cells in their proper tissue 
context (Fukazawa et al. 2002). Therefore, pharmacological agents with ability to inhibit 
both MEK/ERK and PI3/AKT/mTOR signaling pathways could play a role in prevention of 
metastases.
Analysis of cell signaling network interactions reveals that both MEK/ERK and mTOR/
p70S6K pathways can be inhibited by 5′-AMP-activated protein kinase (AMPK). AMPK 
directly phosphor-ylates the TSC2 tumor suppressor on conserved serine sites distinct from 
those targeted by other kinases, leading to the inhibition of mTORC1 (Shaw 2009, Luo et al. 
2010). Recent studies also demonstrated interrelationships between AMPK and mitogenic 
pathways via kinase suppressor of ras 2 (KSR2; Costanzo-Garvey et al. 2009). It has been 
suggested that under metabolic stress, binding of AMPK to KSR2 prevents RAF/MEK to be 
targeted to the plasma membrane for their activation (Luo et al. 2010).
The antidiabetic drug metformin has been shown to be a potent AMPK activator. On the 
intracellular level, metformin inhibits mitochondrial complex I, which leads to an altered 
AMP/ATP ratio and activation of AMPK (El-Mir et al. 2000). Studies on various cancer cell 
lines and animal models demonstrated that metformin inhibits growth via activation of 
AMPK pathway (Shaw 2009, Ben Sahra et al. 2010, Martin-Castillo et al. 2010). A recent 
study demonstrated growth inhibitory effects of metformin on anaplastic thyroid cancer cell 
lines (Chen et al. 2012).
In the current study, we assessed the in vitro effect of metformin on proliferation and 
activation of AKT/mTOR/S6K, MAPK/ERK, and AMPK signaling pathways in MTC-
derived cells. We have also examined the effects of metformin on MTC cell properties that 
are required for development of metastases (migration and resistance to anoikis). We also 
determined the expression of metformin molecular targets in human MTC tissue samples.
Materials and methods
Human thyroid tissue and cell culture
The study protocol was approved by the Institutional Review Boards at the Washington 
Hospital Center and the Uniformed Services University of the Health Sciences. The paraffin-
embedded thyroid tissue samples from 14 patients with MTC were selected from a thyroid 
tumor bank maintained at USUHS. There were 11 samples from patients with sporadic MTC 
and three samples from patients with hereditary MTC (two MEN2A and one familial MTC).
Human medullary thyroid cancer cell lines harboring C634W RET mutation (TT cells) and 
M918T RET mutation (MZ-CRC-1 cells) were obtained from Dr Motoyasu Saji (The Ohio 
State University). Cells were maintained in RPMI1640 medium supplemented with heat-
inactivated 20% fetal bovine serum and 1×nonessential amino acids (1%) at 37 °C and 
humidified 5% CO2. For an in vitro model of anoikis, TT and MZ-CRC-1 cells were 
cultured on poly-HEMA-treated low-adherent plates. Cells were incubated with either 
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control medium or medium containing metformin (Sigma Chemical Co.). The 
pharmacological inhibitor of pAMPK compound C was purchased from EMD Biosciences 
(San Diego, CA, USA).
siRNA transfections
TT cells were transfected with AMPK siRNA specific to α1 and α2 isoforms of catalytic 
subunit or with Stealth RNAi siRNA-negative control (Invitrogen). RNAi duplex–
lipofectamine complexes were prepared using RNAiMAX transfection reagent (Invitrogen 
Corp.). The efficiency of silencing was assessed by Block-it fluorescent reagent and by 
detection of αAMPK protein level. Assays were performed 48 h after the initiation of the 
transfections.
Protein extraction and western blot analysis
Thyroid cancer cells were incubated with ice-cold cell lysis buffer, scraped, centrifuged, and 
the supernatant was stored at −80 °C. Total protein lysate (25 μg) was suspended in reduced 
SDS sample buffer and protein lysates were subjected to SDS–PAGE (7%). The separated 
proteins were transferred to nitro-cellulose membranes (0.2 μm pore size; Invitrogen) by 
electrophoretic blotting (Invitrogen). Nonspecific binding was prevented by blocking with 
0.1% Tween 20 in PBS (PBS-T) containing 5% nonfat dry milk overnight at 4 °C.
Membranes were incubated overnight with the primary antibody against phospho-p70S6K 
(Thr389), total p70S6K, phospho-pS6 (Ser235/236), total pS6, phospho-AKT (Ser473), total 
AKT, phospho-ERK (Thr202/Tyr204), total ERK, phospho-AMPKα (Thr172), total 
AMPKα, PARP, and cleaved caspase 3 (Cell Signaling, Boston, MA, USA); and cyclin D1, 
E-cadherin, and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes 
were then incubated with the secondary antibody in PBS-T containing 5% nonfat dry milk 
for 1 h at room temperature. After washing with PBS-T four times (15 min/wash), protein 
bands on the blots were visualized using Li-COR Odyssey imaging system (LI-COR 
Biosciences, Lincoln, NE, USA).
Cell viability and proliferation assays
Cell viability was determined by Alamar blue assay (Invitrogen) according to the 
manufacturer’s instructions. Cells were plated in 96-well plates and grown until 50% 
confluence was reached. Cells were treated with metformin at concentrations varying from 
0.1 to 5 mM for 24, 48, and 72 h. Ten microliters (10% of sample volume) of Alamar blue 
solution were added to each well, and cells were subsequently returned to the incubator for 4 
h. The absorbance of Alamar blue reagent was monitored at 570 and 600 nM by 
spectrophotometer.
For cell proliferation assay, TT and MZ-CRC-1 cells were plated at a density of 50 000 
cells/well in 6-well plates. Cells were allowed to adhere overnight and then treated with 
metformin at concentrations varying from 0.1 to 5 mM. After incubation for 24, 48, or 72 h, 
cell proliferation rate was determined by cell counting using Vi-CELL Cell Viability 
Analyzer from Beckman Coulter (Fullerton, CA, USA).
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In low-adherent conditions, cell viability was determined by evaluation of mitochondrial 
membrane potential with a fluorogenic lipophilic cation (JC-1; Cayman Chemical Company, 
Ann Arbor, MI, USA). All experiments were repeated at least three times, and the average 
values ±S.D. of representative experiments are reported.
Immunostaining of human thyroid tissue samples
Immunostaining was performed on paraffin-embedded tissue sections. Endogenous 
peroxidase activity was quenched by incubation in 3% hydrogen peroxide. Sections were 
incubated overnight with cyclin D1 or phospho-p70S6K antibodies. Immunostaining was 
performed using Vector kits (Vector Labs, Burlingame, CA, USA) according to the 
manufacturer’s instruction. For quantification of cyclin D1 expression, at least 200 cells in 
three different areas of tumor were examined and percentage of positive nuclei was 
calculated. For phospho-p70S6K staining, the results of staining were interpreted as follows: 
negative – no staining or focal/low intensity of staining in < 20% of cells and positive 
staining – strong staining in more than 20% of cells. The intensity of immunostaining was 
scored independently by two investigators (J Klubo-Gwiezdzinska and V Vasko).
Results
Metformin inhibits growth of medullary thyroid cancer cells
To determine the effects of metformin on MTC-derived cell lines viability, we performed an 
Alamar blue assay. Treatment with increasing concentration of metformin was associated 
with inhibition of TT cell growth in dose- and time-dependent manner (Fig. 1A). Significant 
inhibition of TT cells growth was detected after cell exposure for 72 h with micromolar 
concentration of metformin. In MZ-CRC-1 cells, significant inhibition of growth was 
observed after exposure to metformin at concentration 1 and 5 mM for 48 or 72 h. Direct 
cell counts using Vi-CELL Cell Viability Analyzer confirmed data obtained by Alamar blue 
assay in TT and MZ-CRC-1 cell lines.
The reduction of cell number after treatment with metformin may be the result of either cell 
cycle arrest or cell death. To address this question, we performed western blot analysis with 
antibody against proliferation marker (cyclin D1) and apoptotic markers (cleaved caspase 3 
and PARP). Treatment with metformin was associated with inhibition of cyclin D1 
expression in TT and MZ-CRC-1 cell lines (Fig. 1B) without significant changes in cleavage 
of caspase 3 and PARP. The intensity of immunostaining with antibodies against cyclin D1 
was decreased in metformin-treated cells (Fig. 1C) corroborating western blot data. These 
data indicate that metformin inhibits MTC cell growth through inhibition of proliferation but 
not induction of apoptosis.
Metformin inhibits mTOR signaling in MTC-derived cells
As growth inhibitory effects of metformin in various cancer cell lines were attributed to 
downregulation of mTOR signaling, we next examined activation of well-established 
downstream targets of mTOR-p70S6K and its substrate ribosomal protein S6 using specific 
antibodies. Western blot analysis showed that treatment with metformin was associated with 
dose-dependent inhibition of phosphop-p70-S6K and phospho-pS6 in MTC-derived cells 
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(Fig. 2A). Immunostaining also showed that intensity of immunostaining with anti-phospho-
pS6 was decreased in MTC cells after treatment with metformin (Fig. 2B).
We also examined the effects of metformin on phosphorylation status of AKT, ERK, and 
AMPK in MTC-derived cells by western blot analysis. The level of pAKT was not 
significantly affected by treatment with increasing concentration of metformin in any of the 
examined cell lines (Fig. 2C). Metformin inhibited pERK in both TT and MZ-CR-1 cells. 
Induction of pAMPK was observed in TT cells but not in MZ-CRC-1 cells after treatment 
with metformin (Fig. 2C).
Consistent with the results of western blot analysis, the intensity of immunostaining with 
anti-pAMPK was increased in TT cells treated with metformin (Fig. 2D) but not in MZ-
CRC-1 cells.
The role of AMPK in metformin-inducible mTOR inhibition
To clarify the role of pAMPK in TT cell response to metformin, we performed experiments 
using pharmacological AMPK inhibitor (compound C). Treatment with compound C (2 μM) 
decreased metformin-inducible activation of pAMPK (Fig. 3A). However, compound C did 
not prevent metfromin-inducible inhibition of phospho-pS6 and downregulation of cyclin D1 
in TT cells.
We also performed silencing experiments and examined the effects of metformin on 
αAMPK-deficient TT cells. Combined inhibition of both α1 and a α2 isoforms of catalytic 
subunit prevented metformininducible AMPK activation (Fig. 3B). However, loss of AMPK 
expression did not prevent metformin-inducible downregulation of phospho-pS6 and only 
partially rescued metformin-inducible inhibition of cyclin D1. These results showed that loss 
of AMPK activity is not sufficient to completely abrogate inhibitory effects of metformin on 
mTOR signaling in TT cells.
The effects of metformin on MTC cell migration and resistance to anoikis
We next examined the effects of metformin on migration of MTC-derived cells and their 
resistance to anoikis. TT and MZ-CRC-1 cells intrinsically express E-cadherin and do not 
efficiently migrate through 8 μM pore membrane in the Boyden chamber migration assay. 
Treatment with metformin had no effects on E-cadherin expression and did not affect 
migratory ability of TT or MZ-CRC-1 cells (data not shown).
For analysis of anoikis, TT and MZ-CRC-1 cells were maintained in either adherent cell 
culture plates or low-adherent cell culture conditions. In low-adherent conditions, both 
MTC-derived cell lines were characterized by establishment of cell-to-cell contacts and 
formation of multicellular spheroids. MTC-derived cancer cells that formed spheroids were 
viable as demonstrated by JC-1 staining (Fig. 4A).
To determine whether metformin can affect spheroid formation, we pretreated TT and MZ-
CRC-1 cells for 24 h with increasing concentrations of metformin in adherent plates and 
then transferred these cells into nonadherent plates. As shown in Fig. 4A, the number and 
size of spheroids were decreased in MTC cells pretreated with metformin. The viability of 
Klubo-Gwiezdzinska et al. Page 6
Endocr Relat Cancer. Author manuscript; available in PMC 2018 August 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
these cells was significantly reduced as demonstrated by JC-1 staining. We also performed 
analysis of pro-survival signaling in nonadherent cells. Western blot analysis showed that TT 
and MZ-CRC-1 cells maintained activation of pAKT, pERK, and p70S6K/pS6 in low-
adherent conditions. Pretreatment with metformin resulted in downregulation of pAKT, 
pERK, and p70S6K/pS6 in MTC cells growing in nonadherent conditions (Fig. 4B) and 
induction of apoptosis (Fig. 4C). Together, these data demonstrate that metformin impairs 
MTC cell survival after detachment from extracellular matrix and sensitizes MTC cells to 
anoikis.
Activation of mTOR signaling in human MTCs
Our in vitro findings demonstrated that metformin inhibits cell growth, decreases cyclin D1 
expression, and inhibits mTOR/p70S6K signaling in both MTC-derived cell lines. To 
determine whether these in vitro findings could have relevance in human MTC, we assessed 
expression of cyclin D1 and activation of mTOR/p70S6K signaling in human MTC tissue 
samples. The level of immunostaining with anti-cyclin D1 was increased in all examined 
MTCs compared with the corresponding normal thyroid tissue. Cyclin D1 expression was 
detected in nuclei of MTC cells (Fig. 5A). The number of positive nuclei in tumors varied 
from case to case and ranged from 10 to 60%. The highest level of cyclin D1 expression was 
found in MTC samples from patients with hereditary forms of MTC (two patients with 
MEN2A and one patient with familial MTC).
Immunostaining with phospho-p70S6K was increased in 8/14 (57.1%) examined MTCs 
compared with the corresponding normal thyroid tissue (Fig. 5A). All hereditary MTCs and 
5/11 sporadic MTCs showed strong immunoreactivity with anti-phospho-p70S6K antibody. 
In two cases of widely invasive MTCs, we detected cancer cells that were located inside the 
vessels. Positive immunostaining with p-p70S6K was observed in intravascular MTC cells. 
Together, these data showed that human MTC cells are characterized by increased 
expression of cyclin D1 and activation of mTOR/p70S6K signaling pathway.
Discussion
Targeting cancer cell metabolism is a promising strategy to treat cancer. There is increasing 
evidence of the potential efficacy of a commonly used antidiabetic drug, metformin, as an 
anticancer agent. The primary systemic effect of metformin is thelowering of bloodglucose 
levels through reduction of the hepatic glucose production and increased insulin sensitivity 
enabling appropriate usage of glucose by muscles and adipocytes (Ben Sahra et al. 2010). As 
insulin is a growth-promoting hormone with mitogenic effects, it has been suggested that 
beneficial effects of metformin in cancer patients are related to its systemic insulin-lowering 
effects. However, numerous studies demonstrated that in addition to its systemic action, 
metformin has direct growth inhibitory effects on cancer cells through inhibition of 
mTOR/S6K signaling (Guertin & Sabatini 2007, Ben Sahra et al. 2008, Luo et al. 2010). In 
this study, we used MTC-derived cells to examine the effects of metformin on medullary 
thyroid cancer cell growth, migration, and resistance to anoikis.
Metformin inhibited MTC cell growth in a dose- and time-dependent manner. In fact, MTC 
cells seem to be specifically sensitive to metformin. In contrast to previous studies 
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documenting anticancer effects of millimolar concentrations of metformin in breast, ovarian, 
and pancreatic cancer cell lines, we observed significant inhibition of MTC proliferation 
with micro-molar concentrations applied for 72 h. Inhibition of growth was associated with 
downregulation of cyclin D1 but not induction of apoptosis. Our findings are similar to 
previously reported observations in breast, prostate, and ovarian cancer cell lines showing 
that metformin induces blockade of cell cycle progression in G0/G1 phase (Ben Sahra et al. 
2008, Zhuang & Miskimins 2008). In MTC cells, treatment with metformin resulted in 
inhibition of mTOR signaling pathway as demonstrated by down-regulation of phospho-
p70S6K and phospho-pS6. Activation of p70S6K appears to be necessary for translation of 
specific set of mRNA, encoding ribosomal protein and translation elongation factors (Vesely 
et al. 1994, Sonenberg & Gingras 1998). It has also been demonstrated that expression of 
other genes important for cell cycle progression, such as Myc and cyclin D, may be 
controlled by the p70S6K pathway. These findings could explain the reason why inhibition 
of this pathway induces blockade of proliferation in MTC-derived cancer cells.
We demonstrated that metformin-inducible inhibition of mTOR/S6K signaling was 
associated with increased AMPK phosphorylation only in TT cells but not in MZ-CRC-1 
cell line. Previous studies on breast and ovarian cancer cell lines demonstrated that the 
inhibitory effects of metformin on cancer cell growth were mediated via activation of AMPK 
(Dowling et al. 2007, Gotlieb et al. 2008). In contrast, studies using prostate cancer cells 
showed that metformin inhibits cell growth independently of its effect on AMPK (Ben Sahra 
et al. 2008). In the current study, pharmacological inhibition of AMPK activity or AMPK 
silencing did not prevent metformin-inducible inhibition of growth and downregulation of 
mTOR/S6K signaling in MTC cells. These data suggest that in addition to AMPK, other 
mechanisms could be involved in metformin-inducible downregulation of mTOR/S6K 
signaling and inhibition of cell growth in MTC cells. We also demonstrated that treatment 
with metformin was associated with inhibition of MEK/ERK signaling in TT and MZ-
CRC-1 cells. Taking into consideration the role of both MEK/ERK and mTOR/S6K 
cascades in development of MTC, the dual inhibition of these signaling pathways by 
metformin could represent an attractive strategy for the treatment of MTC.
As local and distant metastases are common in MTC patients, we also examined the effects 
of metformin on cancer cell properties that are required for development of metastases 
(migration and resistance to anoikis). We found that MTC-derived cells were intrinsically 
resistant to anoikis and maintained activation of AKT/mTOR/p-70S6K and ERK signaling 
after detachment from extracellular matrix. Treatment with metformin sensitized MTC cell 
to anoikis and dramatically impaired their ability to survive in nonadherent conditions. 
Resistance to anoikis is a critical element of the metastatic cascade and our findings suggest 
the possible utility of metformin as an agent that may prevent metastases.
These findings are specifically promising because we found increased expression of 
metformin molecular targets in a series of human MTC samples. We found that activation of 
mTOR signaling is common in human MTCs. Positive staining with anti-phospho-p70S6K 
antibody in human MTC cells that invaded vessels corroborated in vitro results and 
suggested the role of mTOR signaling in MTC cell resistance to anoikis. Our results are 
similar to recently published findings (Rapa et al. 2011) demonstrating activation of mTOR/
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p70S6K signaling in patients with MTCs. Taking into consideration that antineoplastic 
effects of metformin are mediated through inhibition of phospho-p70S6K, it is tempting to 
speculate that detection of phospho-p70S6K in samples from MTC patients could represent 
a marker of tumor cell response to the treatment with metformin.
In the current study, growth inhibitory effects of metformin were observed at concentrations 
that were significantly higher than those achievable in humans. The therapeutic 
concentrations of metformin in human serum range from 5 to 20 μM (Dell’Aglio et al. 
2009). It is noted that in animal models, antitumor effects of physiological concentration of 
metformin (3–13 μM) were observed only after chronic exposure (for up to 13 weeks). The 
inhibition of tumor growth was attributed not only to direct effects of metformin on cancer 
cells but also to its indirect effects through diminished levels of circulating growth factors. It 
is possible that a combination of direct effects of metformin on MTC cells with its systemic 
insulin-lowering effects may result in inhibition of MTC growth with concentration that is 
achievable in human.
Retrospective data from population-based studies demonstrated that treatment with 
metformin reduced cancer risk in humans and improved outcome of different cancers. On 
the basis of these studies, metformin is now being used in various clinical trials including in 
a neoadjuvant setting and in combination with other drugs. Our in vitro data showed that 
metformin inhibits growth and induces anoikis in MTC-derived cells. Analysis of human 
MTC samples demonstrated expression of metformin molecular targets in MTC cells. In 
summary, these data suggest that the antidiabetic drug metformin can inhibit growth and 
prevent development of metastases in MTC.
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Figure 1. 
The effects of metformin on MTC cells growth. (A) Dose and time dependent effect of 
metformin on TT and MZ-CRC-1cells growth. The decrement in number of viable cells was 
dependent upon both the concentration of metformin and the duration of exposure (*P value 
<0.05; **P value <0.001). (B) Western Blot analysis demonstrating metformin-inducible 
down-regulation of cyclin D1 expression in dose dependent manner. (C) TT cells were 
grown on LabTech chamber slides and treated with metformin (5 mM) for 24 h. Treatment 
with metformin was associated with inhibition of cyclin D1 expression.
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Figure 2. 
The effects of metformin on cell signaling activation in MTC-derived cells. (A) Western blot 
analysis showing dose dependent inhibition of p-p70-S6K and p-pS6 in TT and MZ-
CRC-1cells treated with metformin. (B) Immunostaining showed decreased phosphorylation 
of pS6 in TT cells treated with metformin (5 mM for 24 h). (C) Western blot analysis 
showing that metformin had no effect on pAkt, but inhibited pERK in TT and MZ-CR-1 
cells. Metformin increased phosphorylation of AMPK in TT cells, but not in MZ-CRC-1 
cells. (D) Immunostaining with anti-pAMPK showed increased immunoreactivity in TT 
cells that were treated with metformin (5 mM for 24 h).
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Figure 3. 
The effect of AMPK inhibitor and AMPK silencing on TT cell response to treatment with 
metformin. (A) TT cells were treated with metformin alone or in combination with the 
AMPK inhibitor compound C. Western blot analysis showing that compound C attenuates 
metformin inducible AMPK phosphorylation with no significant effect on metformin 
inducible down-regulation of p-pS6 and cyclin D1 in TT cells. (B) Silencing of α1 and α2 
isoforms of the catalytic subunit of AMPK attenuated metformin inducible AMPK 
activation, but did not prevent down-regulation of p-pS6 in TT cells. Loss of AMPK only 
partially rescued metformin-inducible inhibition of cyclin D1. **P<0.001.
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Figure 4. 
The effects of metformin on spheroid formation in low adherent condition and detachment 
induced apoptosis (anoikis). (A) After trypsinization TT cells were places on non adherent 
culture plates and morphological changes were monitored by microscopy. At 4 h post-
plating, MTC cells formed multi-cellular conglomerates and at 24 h formed spheroids-like 
structures. Pretreatment with metformin 1 mM/24 h resulted in reduced size and number of 
spheroids and decreased viability of the cells as documented by JC-1 staining. (B) Western 
blot showing that pretreatment with metformin (1 mM/24 h) resulted in significant 
downregulation of pAKT, pERK, p-p70S6K in TT and MZ-CRC-1 cells growing in low 
adherent (LA) conditions compared to the LA cells not pre-treated with metformin. (C) 
Treatment with increasing concentrations of metformin for 24 h did not induce apoptosis in 
adherent TT cells. Pre-treatment with metformin sensitized TT cells to anoikis.
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Figure 5. 
Immunohistochemical staining with anti-p-p70S6K antibody in human thyroid tissue 
samples. The level of p-p70S6K immunostaining is increased in MTC cells compared to 
normal thyroid cells. MTC cells that invaded into the vessel show high level of 
immunoreactivity with anti-p-p70S6K.
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